Europe's leadership in life sciences needs strong frameworks and partnerships – POLITICO

POLITICO Studio speaks with Ricardo Marek, President Europe and Canada at Takeda Pharmaceuticals, on why rare diseases need to be a public health priority, and how Europe can remain a leader in life sciences. 

Related Keywords

Japan ,Tokyo ,Belgium ,Ricardo Marek ,Publications Office Of The European Union ,Population Health Management Through Payer ,European Health Data Space ,European Commission ,Innovative Medicines Initiative Screen ,European Federation Of Pharmaceutical Industries ,Thwaites ,Innovative Medicines Initiative ,O Health Outcomes Observatory ,Public Health ,Health Outcomes Observatory ,Global Health ,European Confederation Of Pharmaceutical Entrepreneurs ,World Economic Forum ,European Organisation For Rare Diseases ,President Europe ,European Federation ,Pharmaceutical Industries ,European Confederation ,Pharmaceutical Entrepreneurs ,European Organisation ,Rare Diseases ,Rare Genetics ,Human Genetics ,Diagnostic Journey ,Int Arch Intern Med ,World Economic ,Humanit Soc Sci Commun ,Outcomes Observatory ,Advanced Therapies ,Medicines Initiative ,Rare Disease Diagnosis ,Using Newborn Genetic Screening ,Digital Technologies ,Publications Office ,Provider Partnerships ,Improving Outcomes ,Healthcare Quality ,Root Cause ,Innovative Medicines ,Patients Have Access ,International Journal ,Technology Assessment ,Health Care ,Health Data Space ,Care Delivery ,Canada ,Clinical Trials ,Czech Republic ,Data ,Digital ,Drug And Device Safety ,France ,Genetics ,Infrastructure ,Innovation ,Major And Chronic Diseases ,Medicines ,Oncology ,Patient Access ,Patients ,Policy ,Public Private Partnerships ,Regulation ,Regulatory ,Research ,Research And Development ,Sweden ,Technology ,Vaccines ,